课题基金 / 基金详情

NEW IN VITRO 3D FUNCTIONAL MODEL OF TUMORIGENESIS

NEW IN VITRO 3D FUNCTIONAL MODEL OF TUMORIGENESIS
肿瘤发生的新体外 3D 功能模型
批准号:
6791742
负责人:
RAJ K. SINGH
金额:
$2.64万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-06-01 至 2004-09-26

项目摘要

项目成果

RAJ K. SINGH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): There is a need for developing an in vitro tumorigenesis model which mimics the in vivo biology of tumors. At present, tumor studies mostly utilize monolayer cell cultures and animal-derived biomatrix systems. The commonly used Matrigel and collagen models exhibit major compositional and biological limitations. Moreover, no well defined functional model is available for examining the important stages of tumor development in humans. DSI recently created a novel human biomatrix system, HuBiogel, for exploring cell-matrix interactions. Its physiologic matrix milieu, unlike existing models, actively supports proliferation, organization and differentiation of epithelial and endothelial cells. Employing this versatile biomatrix technology, DSI proposes to develop new physiologically-relevant (3D) models of human tumor invasion and angiogenesis. These tumor-host bioassay systems would allow analysis of discrete cellular and molecular events of tumor growth and progression in vitro. The Phase I specific goals are: 1. Develop and optimize HuBiogel assay systems using defined biomatrix formulations and 3D cell culture configurations and; 2. Demonstrate practical applications for monitoring key tumorigenesis events using multicellular tumor spheroid cocultures with fibroblasts or endothelial cells. In the second phase of this R&D project, functional studies of new bioassays will be expanded for validation with other human tumor models. The timely development of this clinically relevant model will positively impact cancer biology, drug discovery and therapeutic arenas. Commercial Importance & Significance: No acceptable commercial tumor model currently exists which utilizes a defined human biomatrix system. DSI will develop reusable and disposable 3D tumor invasion and angiogenesis bioassays. Sale of HuBiogel and pre-packed assay systems would have a significant world-wide market, both as a research and diagnostic tool.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New High Throughput Anti-Tumor Drug Screening System
  • 批准号:
    8780336
  • 项目类别:
  • 资助金额:
    $15.7万
  • 财政年份:
    2014
  • 负责人:
    RAJ K. SINGH
  • 依托单位:
New In Vitro Human Liver Toxicity Bioassay System
  • 批准号:
    8458114
  • 项目类别:
  • 资助金额:
    $29.72万
  • 财政年份:
    2010
  • 负责人:
    RAJ K. SINGH
  • 依托单位:
New In Vitro Human Liver Toxicity Bioassay System
  • 批准号:
    7801418
  • 项目类别:
  • 资助金额:
    $13.0万
  • 财政年份:
    2010
  • 负责人:
    RAJ K. SINGH
  • 依托单位:
New In Vitro Human Liver Toxicity Bioassay System
  • 批准号:
    8312109
  • 项目类别:
  • 资助金额:
    $44.18万
  • 财政年份:
    2010
  • 负责人:
    RAJ K. SINGH
  • 依托单位:
国内基金
海外基金
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
  • 批准号:
    82372007
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    谢文晖
  • 依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
  • 批准号:
    82371726
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    李文
  • 依托单位:
RNA编辑型IGFBP7在肿瘤细胞与肿瘤血管微环境中的调控作用及机制研究
  • 批准号:
    32070790
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    徐小燕
  • 依托单位:
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
  • 批准号:
    81200692
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    陈凌
  • 依托单位: